ArticleAMB Express2025
Design a multi-epitope vaccine candidate against Acinetobacter baumannii using advanced computational methods.
Article in AMB Express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Green-Synthesized Silver Nanoparticles Against Acinetobacter baumannii: A Systematic Review of Antibacterial Activity, Mechanisms of Action, Toxicity, and Antibiofilm Effects.MicrobiologyOpen · 2026Pooled it
- Harnessing epitope reciprocity and multimeric epitope density for a novel multiepitope vaccine design against Acinetobacter baumannii.Scientific reports · 2026Article
- A multi-epitope pan-betacoronavirus vaccine construct predicted to induce broad-spectrum and durable immune responses: an immunoinformatics approach.Frontiers in bioinformatics · 2026Article
- Decoding GuaB: Machine Learning-Powered Discovery of Enzyme Inhibitors Against the SuperbugPharmaceuticals (Basel, Switzerland) · 2025Article
- In silico design and assessment of a multi-epitope peptide vaccine against multidrug-resistantIn silico pharmacology · 2025Article
- Development of a multi-epitope vaccine against Acinetobacter baumannii: A comprehensive approach to combating antimicrobial resistance.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter baumannii is a significant cause of hospital-acquired infections and is often resistant to multiple antibiotics. In this study, we designed a multi-epitope vaccine candidate using the outer membrane protein K (OmpK) of A. baumannii. T-cell and B-cell epitopes were predicted, and the best epitopes were selected for multi-epitope design. For selecting the best epitopes, many in silico studies, as well as molecular docking of epitope-HLAs, were performed. The multi-epitope was designed using β-defensin as an adjuvant, PADRE sequence as an immunogenicity enhancer, and appropriate linkers. The tertiary structure of the multi-epitope was obtained using modeling and several molecular dynamics (MD)-based refinements. The sequence and/or 3D model of the multi-epitope was investigated for physicochemical, structural, in silico cloning, conformational B epitope prediction, immune response simulation, molecular docking for assay binding to toll-like receptors (TLRs), and deformability studies. The results showed that the multi-epitope construct is favorable in the case of immunogenicity, physicochemical properties, structure, binding to TLRs, solubility, stability, toxicity, allergenicity, and cross-reactivity. This multi-epitope vaccine candidate has the potential to elicit multiple immune responses against A. baumannii. However, in vitro and in vivo experimental tests are needed to validate its efficacy as a potential vaccine candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.